Research programme: fusion proteins - SymphogenAlternative Names: RB 200; RBLX-200; RBLX-242; Sym 011
Latest Information Update: 10 May 2013
At a glance
- Originator Receptor BioLogix
- Developer Symphogen
- Class Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Epidermal growth factor receptor modulators; ERBB-3 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer